Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL +4.98%64 EBITDA Margin % is 11.20% as of Sep. 2025, which is 25% below its 10-year median of 14.97. GuruFocus rates ZJYL with a GF Score™ of 64/100 and a GF Value™ of $14.58 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Jin Medical International ranks worse than 55.64% on this metric.
Jin Medical International (NAS:ZJYL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jin Medical International EBITDA Margin % Related Terms
Jin Medical International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZJYL vs RVP, CUPR, BNGO: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Jin Medical International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jin Medical International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International (ZJYL) has a EBITDA Margin % of 11.20% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jin Medical International and its competitors. This is 25% below median its historical median of 14.97. Over the past decade, Jin Medical International's EBITDA Margin % has ranged from 4.64 to 17.26. According to the industry distribution chart, Jin Medical International ranks #454 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 55.6%.
Is Jin Medical International's EBITDA Margin % too high?
Jin Medical International's current EBITDA Margin % of 11.20% is 25% below median its 10-year median of 14.97. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 17.26. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Jin Medical International's value of 11.20% is 50.2% above this industry median. Based on the distribution chart, Jin Medical International ranks #454 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's EBITDA Margin % compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #454 out of 816 companies for EBITDA Margin %. This places Jin Medical International in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Jin Medical International's value of 11.20% is 50.2% above this benchmark. Historically, Jin Medical International's own EBITDA Margin % has ranged from 4.64 to 17.26 over the past decade. While the company's 10-year median is 14.97 vs. the industry median of 7.46, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current EBITDA Margin % of 11.20% is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current EBITDA Margin % is 11.20%, which is 25% below median its own 10-year median of 14.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.96 — trading 86.6% below its estimated fair value. The current EBITDA Margin % is 11.20%, which is 25% below median its 10-year median of 14.97 and 50.2% above the Medical Devices & Instruments industry median of 7.46. Jin Medical International's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current EBITDA Margin % is 11.20% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $1.96 is trading 86.6% below its estimated GF Value™ of $14.58.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
EBITDA Margin %: 11.20% (25% below median its 10-year median of 14.97)
GF Value™: $14.58 vs. price of $1.96 (86.6% below fair value)
Industry Position: 50.2% above the Medical Devices & Instruments median (#454 of 816)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
